Autophagy in cancer associated fibroblasts promotes tumor cell survival Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment
Recently, using a co-culture system, we demonstrated that MCF7 epithelial cancer cells induce oxidative stress in adjacent cancer-associated fibroblasts, resulting in the autophagic/lysosomal degradation of stromal caveolin-1 (Cav-1). However, the detailed signaling mechanism(s) underlying this proc...
Saved in:
| Published in: | Cell cycle (Georgetown, Tex.) Vol. 9; no. 17; pp. 3515 - 3533 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Taylor & Francis
01.09.2010
Landes Bioscience |
| Subjects: | |
| ISSN: | 1538-4101, 1551-4005, 1551-4005 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Recently, using a co-culture system, we demonstrated that MCF7 epithelial cancer cells induce oxidative stress in adjacent cancer-associated fibroblasts, resulting in the autophagic/lysosomal degradation of stromal caveolin-1 (Cav-1). However, the detailed signaling mechanism(s) underlying this process remain largely unknown. Here, we show that hypoxia is sufficient to induce the autophagic degradation of Cav-1 in stromal fibroblasts, which is blocked by the lysosomal inhibitor chloroquine. Concomitant with the hypoxia-induced degradation of Cav-1, we see the upregulation of a number of well-established autophagy/mitophagy markers, namely LC3, ATG16L, BNIP3, BNIP3L, HIF-1α and NFκB. In addition, pharmacological activation of HIF-1α drives Cav-1 degradation, while pharmacological inactivation of HIF-1 prevents the downregulation of Cav-1. Similarly, pharmacological inactivation of NFκB-another inducer of autophagy-prevents Cav-1 degradation. Moreover, treatment with an inhibitor of glutathione synthase, namely BSO, which induces oxidative stress via depletion of the reduced glutathione pool, is sufficient to induce the autophagic degradation of Cav-1. Thus, it appears that oxidative stress mediated induction of HIF1- and NFκB-activation in fibroblasts drives the autophagic degradation of Cav-1. In direct support of this hypothesis, we show that MCF7 cancer cells activate HIF-1α- and NFκB-driven luciferase reporters in adjacent cancer-associated fibroblasts, via a paracrine mechanism. Consistent with these findings, acute knock-down of Cav-1 in stromal fibroblasts, using an siRNA approach, is indeed sufficient to induce autophagy, with the upregulation of both lysosomal and mitophagy markers. How does the loss of stromal Cav-1 and the induction of stromal autophagy affect cancer cell survival? Interestingly, we show that a loss of Cav-1 in stromal fibroblasts protects adjacent cancer cells against apoptotic cell death. Thus, autophagic cancer-associated fibroblasts, in addition to providing recycled nutrients for cancer cell metabolism, also play a protective role in preventing the death of adjacent epithelial cancer cells. We demonstrate that cancer-associated fibroblasts upregulate the expression of TIGAR in adjacent epithelial cancer cells, thereby conferring resistance to apoptosis and autophagy. Finally, the mammary fat pads derived from Cav-1 (-/-) null mice show a hypoxia-like response in vivo, with the upregulation of autophagy markers, such as LC3 and BNIP3L. Taken together, our results provide direct support for the "Autophagic Tumor Stroma Model of Cancer Metabolism," and explain the exceptional prognostic value of a loss of stromal Cav-1 in cancer patients. Thus, a loss of stromal fibroblast Cav-1 is a biomarker for chronic hypoxia, oxidative stress and autophagy in the tumor microenvironment, consistent with its ability to predict early tumor recurrence, lymph node metastasis and tamoxifen-resistance in human breast cancers. Our results imply that cancer patients lacking stromal Cav-1 should benefit from HIF-inhibitors, NFκB-inhibitors, anti-oxidant therapies, as well as autophagy/lysosomal inhibitors. These complementary targeted therapies could be administered either individually or in combination, to prevent the onset of autophagy in the tumor stromal compartment, which results in a "lethal" tumor microenvironment. |
|---|---|
| AbstractList | Recently, using a co-culture system, we demonstrated that MCF7 epithelial cancer cells induce oxidative stress in adjacent cancer-associated fibroblasts, resulting in the autophagic/lysosomal degradation of stromal caveolin-1 (Cav-1). However, the detailed signaling mechanism(s) underlying this process remain largely unknown. Here, we show that hypoxia is sufficient to induce the autophagic degradation of Cav-1 in stromal fibroblasts, which is blocked by the lysosomal inhibitor chloroquine. Concomitant with the hypoxia-induced degradation of Cav-1, we see the upregulation of a number of well-established autophagy/mitophagy markers, namely LC3, ATG16L, BNIP3, BNIP3L, HIF-1α and NFκB. In addition, pharmacological activation of HIF-1α drives Cav-1 degradation, while pharmacological inactivation of HIF-1 prevents the downregulation of Cav-1. Similarly, pharmacological inactivation of NFκB—another inducer of autophagy—prevents Cav-1 degradation. Moreover, treatment with an inhibitor of glutathione synthase, namely BSO, which induces oxidative stress via depletion of the reduced glutathione pool, is sufficient to induce the autophagic degradation of Cav-1. Thus, it appears that oxidative stress mediated induction of HIF1- and NFκB-activation in fibroblasts drives the autophagic degradation of Cav-1. In direct support of this hypothesis, we show that MCF7 cancer cells activate HIF-1α- and NFκB-driven luciferase reporters in adjacent cancer-associated fibroblasts, via a paracrine mechanism. Consistent with these findings, acute knockdown of Cav-1 in stromal fibroblasts, using an siRNA approach, is indeed sufficient to induce autophagy, with the upregulation of both lysosomal and mitophagy markers. How does the loss of stromal Cav-1 and the induction of stromal autophagy affect cancer cell survival? Interestingly, we show that a loss of Cav-1 in stromal fibroblasts protects adjacent cancer cells against apoptotic cell death. Thus, autophagic cancer-associated fibroblasts, in addition to providing recycled nutrients for cancer cell metabolism, also play a protective role in preventing the death of adjacent epithelial cancer cells. We demonstrate that cancer-associated fibroblasts upregulate the expression of TIGAR in adjacent epithelial cancer cells, thereby conferring resistance to apoptosis and autophagy. Finally, the mammary fat pads derived from Cav-1 (−/−) null mice show a hypoxia-like response in vivo, with the upregulation of autophagy markers, such as LC3 and BNIP3L. Taken together, our results provide direct support for the “autophagic tumor stroma model of cancer metabolism”, and explain the exceptional prognostic value of a loss of stromal Cav-1 in cancer patients. Thus, a loss of stromal fibroblast Cav-1 is a biomarker for chronic hypoxia, oxidative stress and autophagy in the tumor microenvironment, consistent with its ability to predict early tumor recurrence, lymph node metastasis and tamoxifen-resistance in human breast cancers. Our results imply that cancer patients lacking stromal Cav-1 should benefit from HIF-inhibitors, NFκB-inhibitors, anti-oxidant therapies, as well as autophagy/lysosomal inhibitors. These complementary targeted therapies could be administered either individually or in combination, to prevent the onset of autophagy in the tumor stromal compartment, which results in a “lethal” tumor microenvironment. Recently, using a co-culture system, we demonstrated that MCF7 epithelial cancer cells induce oxidative stress in adjacent cancer-associated fibroblasts, resulting in the autophagic/lysosomal degradation of stromal caveolin-1 (Cav-1). However, the detailed signaling mechanism(s) underlying this process remain largely unknown. Here, we show that hypoxia is sufficient to induce the autophagic degradation of Cav-1 in stromal fibroblasts, which is blocked by the lysosomal inhibitor chloroquine. Concomitant with the hypoxia-induced degradation of Cav-1, we see the upregulation of a number of well-established autophagy/mitophagy markers, namely LC3, ATG16L, BNIP3, BNIP3L, HIF-1α and NFκB. In addition, pharmacological activation of HIF-1α drives Cav-1 degradation, while pharmacological inactivation of HIF-1 prevents the downregulation of Cav-1. Similarly, pharmacological inactivation of NFκB--another inducer of autophagy-prevents Cav-1 degradation. Moreover, treatment with an inhibitor of glutathione synthase, namely BSO, which induces oxidative stress via depletion of the reduced glutathione pool, is sufficient to induce the autophagic degradation of Cav-1. Thus, it appears that oxidative stress mediated induction of HIF1- and NFκB-activation in fibroblasts drives the autophagic degradation of Cav-1. In direct support of this hypothesis, we show that MCF7 cancer cells activate HIF-1α- and NFκB-driven luciferase reporters in adjacent cancer-associated fibroblasts, via a paracrine mechanism. Consistent with these findings, acute knock-down of Cav-1 in stromal fibroblasts, using an siRNA approach, is indeed sufficient to induce autophagy, with the upregulation of both lysosomal and mitophagy markers. How does the loss of stromal Cav-1 and the induction of stromal autophagy affect cancer cell survival? Interestingly, we show that a loss of Cav-1 in stromal fibroblasts protects adjacent cancer cells against apoptotic cell death. Thus, autophagic cancer-associated fibroblasts, in addition to providing recycled nutrients for cancer cell metabolism, also play a protective role in preventing the death of adjacent epithelial cancer cells. We demonstrate that cancer-associated fibroblasts upregulate the expression of TIGAR in adjacent epithelial cancer cells, thereby conferring resistance to apoptosis and autophagy. Finally, the mammary fat pads derived from Cav-1 (-/-) null mice show a hypoxia-like response in vivo, with the upregulation of autophagy markers, such as LC3 and BNIP3L. Taken together, our results provide direct support for the "Autophagic Tumor Stroma Model of Cancer Metabolism", and explain the exceptional prognostic value of a loss of stromal Cav-1 in cancer patients. Thus, a loss of stromal fibroblast Cav-1 is a biomarker for chronic hypoxia, oxidative stress and autophagy in the tumor microenvironment, consistent with its ability to predict early tumor recurrence, lymph node metastasis and tamoxifen-resistance in human breast cancers. Our results imply that cancer patients lacking stromal Cav-1 should benefit from HIF-inhibitors, NFκB-inhibitors, anti-oxidant therapies, as well as autophagy/lysosomal inhibitors. These complementary targeted therapies could be administered either individually or in combination, to prevent the onset of autophagy in the tumor stromal compartment, which results in a "lethal" tumor microenvironment.Recently, using a co-culture system, we demonstrated that MCF7 epithelial cancer cells induce oxidative stress in adjacent cancer-associated fibroblasts, resulting in the autophagic/lysosomal degradation of stromal caveolin-1 (Cav-1). However, the detailed signaling mechanism(s) underlying this process remain largely unknown. Here, we show that hypoxia is sufficient to induce the autophagic degradation of Cav-1 in stromal fibroblasts, which is blocked by the lysosomal inhibitor chloroquine. Concomitant with the hypoxia-induced degradation of Cav-1, we see the upregulation of a number of well-established autophagy/mitophagy markers, namely LC3, ATG16L, BNIP3, BNIP3L, HIF-1α and NFκB. In addition, pharmacological activation of HIF-1α drives Cav-1 degradation, while pharmacological inactivation of HIF-1 prevents the downregulation of Cav-1. Similarly, pharmacological inactivation of NFκB--another inducer of autophagy-prevents Cav-1 degradation. Moreover, treatment with an inhibitor of glutathione synthase, namely BSO, which induces oxidative stress via depletion of the reduced glutathione pool, is sufficient to induce the autophagic degradation of Cav-1. Thus, it appears that oxidative stress mediated induction of HIF1- and NFκB-activation in fibroblasts drives the autophagic degradation of Cav-1. In direct support of this hypothesis, we show that MCF7 cancer cells activate HIF-1α- and NFκB-driven luciferase reporters in adjacent cancer-associated fibroblasts, via a paracrine mechanism. Consistent with these findings, acute knock-down of Cav-1 in stromal fibroblasts, using an siRNA approach, is indeed sufficient to induce autophagy, with the upregulation of both lysosomal and mitophagy markers. How does the loss of stromal Cav-1 and the induction of stromal autophagy affect cancer cell survival? Interestingly, we show that a loss of Cav-1 in stromal fibroblasts protects adjacent cancer cells against apoptotic cell death. Thus, autophagic cancer-associated fibroblasts, in addition to providing recycled nutrients for cancer cell metabolism, also play a protective role in preventing the death of adjacent epithelial cancer cells. We demonstrate that cancer-associated fibroblasts upregulate the expression of TIGAR in adjacent epithelial cancer cells, thereby conferring resistance to apoptosis and autophagy. Finally, the mammary fat pads derived from Cav-1 (-/-) null mice show a hypoxia-like response in vivo, with the upregulation of autophagy markers, such as LC3 and BNIP3L. Taken together, our results provide direct support for the "Autophagic Tumor Stroma Model of Cancer Metabolism", and explain the exceptional prognostic value of a loss of stromal Cav-1 in cancer patients. Thus, a loss of stromal fibroblast Cav-1 is a biomarker for chronic hypoxia, oxidative stress and autophagy in the tumor microenvironment, consistent with its ability to predict early tumor recurrence, lymph node metastasis and tamoxifen-resistance in human breast cancers. Our results imply that cancer patients lacking stromal Cav-1 should benefit from HIF-inhibitors, NFκB-inhibitors, anti-oxidant therapies, as well as autophagy/lysosomal inhibitors. These complementary targeted therapies could be administered either individually or in combination, to prevent the onset of autophagy in the tumor stromal compartment, which results in a "lethal" tumor microenvironment. Recently, using a co-culture system, we demonstrated that MCF7 epithelial cancer cells induce oxidative stress in adjacent cancer-associated fibroblasts, resulting in the autophagic/lysosomal degradation of stromal caveolin-1 (Cav-1). However, the detailed signaling mechanism(s) underlying this process remain largely unknown. Here, we show that hypoxia is sufficient to induce the autophagic degradation of Cav-1 in stromal fibroblasts, which is blocked by the lysosomal inhibitor chloroquine. Concomitant with the hypoxia-induced degradation of Cav-1, we see the upregulation of a number of well-established autophagy/mitophagy markers, namely LC3, ATG16L, BNIP3, BNIP3L, HIF-1α and NFκB. In addition, pharmacological activation of HIF-1α drives Cav-1 degradation, while pharmacological inactivation of HIF-1 prevents the downregulation of Cav-1. Similarly, pharmacological inactivation of NFκB--another inducer of autophagy-prevents Cav-1 degradation. Moreover, treatment with an inhibitor of glutathione synthase, namely BSO, which induces oxidative stress via depletion of the reduced glutathione pool, is sufficient to induce the autophagic degradation of Cav-1. Thus, it appears that oxidative stress mediated induction of HIF1- and NFκB-activation in fibroblasts drives the autophagic degradation of Cav-1. In direct support of this hypothesis, we show that MCF7 cancer cells activate HIF-1α- and NFκB-driven luciferase reporters in adjacent cancer-associated fibroblasts, via a paracrine mechanism. Consistent with these findings, acute knock-down of Cav-1 in stromal fibroblasts, using an siRNA approach, is indeed sufficient to induce autophagy, with the upregulation of both lysosomal and mitophagy markers. How does the loss of stromal Cav-1 and the induction of stromal autophagy affect cancer cell survival? Interestingly, we show that a loss of Cav-1 in stromal fibroblasts protects adjacent cancer cells against apoptotic cell death. Thus, autophagic cancer-associated fibroblasts, in addition to providing recycled nutrients for cancer cell metabolism, also play a protective role in preventing the death of adjacent epithelial cancer cells. We demonstrate that cancer-associated fibroblasts upregulate the expression of TIGAR in adjacent epithelial cancer cells, thereby conferring resistance to apoptosis and autophagy. Finally, the mammary fat pads derived from Cav-1 (-/-) null mice show a hypoxia-like response in vivo, with the upregulation of autophagy markers, such as LC3 and BNIP3L. Taken together, our results provide direct support for the "Autophagic Tumor Stroma Model of Cancer Metabolism", and explain the exceptional prognostic value of a loss of stromal Cav-1 in cancer patients. Thus, a loss of stromal fibroblast Cav-1 is a biomarker for chronic hypoxia, oxidative stress and autophagy in the tumor microenvironment, consistent with its ability to predict early tumor recurrence, lymph node metastasis and tamoxifen-resistance in human breast cancers. Our results imply that cancer patients lacking stromal Cav-1 should benefit from HIF-inhibitors, NFκB-inhibitors, anti-oxidant therapies, as well as autophagy/lysosomal inhibitors. These complementary targeted therapies could be administered either individually or in combination, to prevent the onset of autophagy in the tumor stromal compartment, which results in a "lethal" tumor microenvironment. |
| Author | Capozza, Franco Zhou, Jie Pavlides, Stephanos Caro, Jaime Martinez-Cantarin, Maria P. Martinez-Outschoorn, Ubaldo E. Wang, Chenguang Howell, Anthony Lisanti, Michael P. Trimmer, Casey Whitaker-Menezes, Diana Witkiewicz, Agnieszka K. Sotgia, Federica Pestell, Richard G. Lin, Zhao Chiavarina, Barbara Flomenberg, Neal |
| AuthorAffiliation | 2 The Jefferson Stem Cell Biology and Regenerative Medicine Center; Thomas Jefferson University; Philadelphia, PA USA 5 Department of Pathology; Jefferson Center for Pancreatic, Biliary and Related Cancers; Thomas Jefferson University; Philadelphia, PA USA 6 Manchester Breast Centre & Breakthrough Breast Cancer Research Unit; Paterson Institute for Cancer Research; School of Cancer; Enabling Sciences and Technology; Manchester Academic Health Science Centre; University of Manchester; Manchester, UK 1 Department of Medical Oncology; Thomas Jefferson University; Philadelphia, PA USA 7 Division of Hematology; Department of Medicine; Cardeza Foundation; Thomas Jefferson University; Philadelphia, PA USA 4 Division of Nephrology; Department of Medicine; Thomas Jefferson University; Philadelphia, PA USA 3 Departments of Stem Cell Biology & Regenerative Medicine and Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA |
| AuthorAffiliation_xml | – name: 5 Department of Pathology; Jefferson Center for Pancreatic, Biliary and Related Cancers; Thomas Jefferson University; Philadelphia, PA USA – name: 7 Division of Hematology; Department of Medicine; Cardeza Foundation; Thomas Jefferson University; Philadelphia, PA USA – name: 6 Manchester Breast Centre & Breakthrough Breast Cancer Research Unit; Paterson Institute for Cancer Research; School of Cancer; Enabling Sciences and Technology; Manchester Academic Health Science Centre; University of Manchester; Manchester, UK – name: 2 The Jefferson Stem Cell Biology and Regenerative Medicine Center; Thomas Jefferson University; Philadelphia, PA USA – name: 1 Department of Medical Oncology; Thomas Jefferson University; Philadelphia, PA USA – name: 4 Division of Nephrology; Department of Medicine; Thomas Jefferson University; Philadelphia, PA USA – name: 3 Departments of Stem Cell Biology & Regenerative Medicine and Cancer Biology; Kimmel Cancer Center; Thomas Jefferson University; Philadelphia, PA USA |
| Author_xml | – sequence: 1 givenname: Ubaldo E. surname: Martinez-Outschoorn fullname: Martinez-Outschoorn, Ubaldo E. – sequence: 2 givenname: Casey surname: Trimmer fullname: Trimmer, Casey – sequence: 3 givenname: Zhao surname: Lin fullname: Lin, Zhao – sequence: 4 givenname: Diana surname: Whitaker-Menezes fullname: Whitaker-Menezes, Diana – sequence: 5 givenname: Barbara surname: Chiavarina fullname: Chiavarina, Barbara – sequence: 6 givenname: Jie surname: Zhou fullname: Zhou, Jie – sequence: 7 givenname: Chenguang surname: Wang fullname: Wang, Chenguang – sequence: 8 givenname: Stephanos surname: Pavlides fullname: Pavlides, Stephanos – sequence: 9 givenname: Maria P. surname: Martinez-Cantarin fullname: Martinez-Cantarin, Maria P. – sequence: 10 givenname: Franco surname: Capozza fullname: Capozza, Franco – sequence: 11 givenname: Agnieszka K. surname: Witkiewicz fullname: Witkiewicz, Agnieszka K. – sequence: 12 givenname: Neal surname: Flomenberg fullname: Flomenberg, Neal – sequence: 13 givenname: Anthony surname: Howell fullname: Howell, Anthony – sequence: 14 givenname: Richard G. surname: Pestell fullname: Pestell, Richard G. – sequence: 15 givenname: Jaime surname: Caro fullname: Caro, Jaime – sequence: 16 givenname: Michael P. surname: Lisanti fullname: Lisanti, Michael P. email: federica.sotgia@jefferson.edu – sequence: 17 givenname: Federica surname: Sotgia fullname: Sotgia, Federica email: federica.sotgia@jefferson.edu |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/20855962$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFUk1rFDEYDlKxH3r0KnPzNGsy-b4IZdFaKPSi55BJMt1IZjImmZX9983u1kWL4imBPF_v--QSnE1xcgC8RXBFEEMfjFnJFeIr1MlOvAAXiFLUEgjp2f6ORUsQROfgMufvEHaCS_QKnHdQUCpZdwFurpcS541-2DV-aoyejEuNzjkar4uzzeD7FPugc8nNnOIYi8tNWcaYGuNCaPKStn6rw2vwctAhuzdP5xX49vnT1_WX9u7-5nZ9fdcaIrrSYsdIL6CkuGd9p6Ek1EqOxNBzwTS11klGrRB24DUg4RANkguqMWd1FojxFfh41J2XfnTWuKkkHdSc_KjTTkXt1Z8vk9-oh7hVGBLOEK8C758EUvyxuFzU6PN-FD25uGTFKWMM4oPVu9-tTh6_llcB7RFgUsw5ueEEQVDty1HGKKkQV4dyKh4_wxtfdPFxn9SHf7LIkVUTWpd7H7PxrvZ0crtfSjabGNO0Xh-Isx0qDf6HVm10Kt4Ed3ISR4qfhphG_TOmYFXRuxDTkOrX8Fnhv4d8BAwVy6g |
| CitedBy_id | crossref_primary_10_1089_ars_2013_5292 crossref_primary_10_3390_ph8040675 crossref_primary_10_3389_fimmu_2024_1308070 crossref_primary_10_3389_fcell_2020_00282 crossref_primary_10_1308_rcsann_2017_0024 crossref_primary_10_4161_cc_9_17_12908 crossref_primary_10_1002_jcb_24303 crossref_primary_10_1016_j_bbcan_2023_189029 crossref_primary_10_1146_annurev_pathol_011811_120856 crossref_primary_10_1007_s10330_022_0573_3 crossref_primary_10_1111_j_1349_7006_2011_01985_x crossref_primary_10_1186_s12885_016_2270_9 crossref_primary_10_3390_ijms18092016 crossref_primary_10_3389_fonc_2016_00226 crossref_primary_10_1016_j_bbadis_2012_10_013 crossref_primary_10_1053_j_seminoncol_2013_04_016 crossref_primary_10_1158_0008_5472_CAN_16_0425 crossref_primary_10_3389_fonc_2017_00211 crossref_primary_10_1186_s13046_020_01611_0 crossref_primary_10_1002_pmic_201700167 crossref_primary_10_3390_cancers6031363 crossref_primary_10_1038_aps_2015_159 crossref_primary_10_1080_15548627_2016_1196317 crossref_primary_10_1177_1010428318756203 crossref_primary_10_1038_leu_2015_289 crossref_primary_10_3390_cancers11081191 crossref_primary_10_3390_biomedicines5020029 crossref_primary_10_3389_fonc_2015_00158 crossref_primary_10_1007_s13402_023_00884_9 crossref_primary_10_4161_cc_10_13_16227 crossref_primary_10_1002_1878_0261_13077 crossref_primary_10_1111_exd_14063 crossref_primary_10_1186_s13630_016_0027_3 crossref_primary_10_3389_fcell_2023_1089068 crossref_primary_10_1371_journal_pone_0097580 crossref_primary_10_3390_metabo12030213 crossref_primary_10_3892_ol_2012_1015 crossref_primary_10_1080_07357907_2019_1651328 crossref_primary_10_1186_s12885_015_1030_6 crossref_primary_10_4161_cc_22776 crossref_primary_10_3390_ijms18061297 crossref_primary_10_1038_s41598_017_13006_x crossref_primary_10_3390_jcm6010007 crossref_primary_10_1186_bcr3472 crossref_primary_10_4161_cc_10_23_18254 crossref_primary_10_1016_j_pan_2011_11_003 crossref_primary_10_1007_s10911_018_9402_6 crossref_primary_10_1016_j_celrep_2025_115432 crossref_primary_10_3390_cells8030234 crossref_primary_10_1093_carcin_bgv067 crossref_primary_10_4161_cc_10_12_16002 crossref_primary_10_3390_metabo15040221 crossref_primary_10_1139_bcb_2015_0120 crossref_primary_10_3390_cells13050408 crossref_primary_10_1016_j_biopha_2018_03_165 crossref_primary_10_1080_07853890_2023_2241472 crossref_primary_10_4161_cc_20920 crossref_primary_10_1002_2211_5463_12628 crossref_primary_10_4161_cc_22786 crossref_primary_10_1002_cbin_11326 crossref_primary_10_1155_2019_6240505 crossref_primary_10_4161_cc_24289 crossref_primary_10_1242_dmm_028332 crossref_primary_10_1038_s41420_024_02226_6 crossref_primary_10_1186_s13046_019_1172_5 crossref_primary_10_1038_s41598_025_07201_4 crossref_primary_10_3389_fcell_2020_00630 crossref_primary_10_1016_j_bbcan_2020_188443 crossref_primary_10_1007_s00109_014_1124_7 crossref_primary_10_1186_s12935_021_02121_5 crossref_primary_10_1016_j_addr_2014_09_009 crossref_primary_10_1177_1758834014521111 crossref_primary_10_1016_j_jbior_2014_05_003 crossref_primary_10_3390_ijms19123773 crossref_primary_10_3390_ijms21155486 crossref_primary_10_4161_cc_10_23_18151 crossref_primary_10_1189_jlb_3HI0715_305R crossref_primary_10_1016_j_bbrc_2016_10_088 crossref_primary_10_1016_j_pharmthera_2011_03_009 crossref_primary_10_3390_cancers14020322 crossref_primary_10_3390_cancers14092291 crossref_primary_10_3390_v9120389 crossref_primary_10_1038_nrc3915 crossref_primary_10_2174_0929867331666230719142202 crossref_primary_10_1007_s11626_018_0231_0 crossref_primary_10_1016_j_molmed_2013_05_002 crossref_primary_10_1074_jbc_RA118_002727 crossref_primary_10_1186_s13058_022_01548_6 crossref_primary_10_4161_cc_10_8_15330 crossref_primary_10_1016_j_clcc_2017_10_013 crossref_primary_10_4161_cc_10_13_16233 crossref_primary_10_1186_s13045_021_01087_1 crossref_primary_10_1186_1741_7015_9_62 crossref_primary_10_3389_fonc_2022_862743 crossref_primary_10_4161_cc_10_11_15659 crossref_primary_10_3389_fendo_2022_1044670 crossref_primary_10_3389_fimmu_2025_1648757 crossref_primary_10_1158_1078_0432_CCR_12_2123 crossref_primary_10_4161_cc_11_6_19530 crossref_primary_10_4161_cc_9_21_13817 crossref_primary_10_3892_or_2016_4660 crossref_primary_10_1038_s41568_019_0222_9 crossref_primary_10_1002_med_21531 crossref_primary_10_1016_j_semcancer_2013_06_007 crossref_primary_10_1007_s00404_021_06137_0 crossref_primary_10_1155_2016_1716341 crossref_primary_10_3389_fendo_2023_1083048 crossref_primary_10_3390_cancers13040864 crossref_primary_10_1186_s12943_016_0558_7 crossref_primary_10_1042_BCJ20170164 crossref_primary_10_4161_cc_21884 crossref_primary_10_1002_biot_201600084 crossref_primary_10_1007_s10555_011_9340_x crossref_primary_10_4161_cc_21643 crossref_primary_10_1042_BCJ20170847 crossref_primary_10_3892_ijmm_2017_3267 crossref_primary_10_1155_2021_6645220 crossref_primary_10_1016_j_brainresbull_2019_09_012 crossref_primary_10_1089_ars_2019_7898 crossref_primary_10_1016_j_mad_2011_11_001 crossref_primary_10_1016_j_biocel_2011_01_023 crossref_primary_10_1016_j_coisb_2021_100377 crossref_primary_10_4161_cc_11_2_19006 crossref_primary_10_1038_bjc_2013_768 crossref_primary_10_1042_BCJ20210676 crossref_primary_10_3390_biomedicines9121942 crossref_primary_10_1002_jnr_23431 crossref_primary_10_1007_s13277_014_2156_x crossref_primary_10_1038_onc_2011_220 crossref_primary_10_3389_fonc_2018_00331 crossref_primary_10_4161_cc_25695 crossref_primary_10_1016_j_semcancer_2015_09_011 crossref_primary_10_1155_2014_375325 crossref_primary_10_1016_j_bbrc_2024_150308 crossref_primary_10_4103_sjg_SJG_483_16 crossref_primary_10_3390_cells13050447 crossref_primary_10_1038_s41419_022_05351_1 crossref_primary_10_3390_biomedicines11041130 crossref_primary_10_3390_ijms21010080 crossref_primary_10_1016_j_lfs_2015_04_012 crossref_primary_10_3389_fimmu_2021_767939 crossref_primary_10_1007_s12032_024_02417_2 crossref_primary_10_1016_j_jsbmb_2011_12_004 crossref_primary_10_1016_j_omto_2021_10_005 crossref_primary_10_2147_OTT_S312003 crossref_primary_10_4161_cc_21384 crossref_primary_10_1016_j_toxrep_2024_101863 crossref_primary_10_4161_cc_10_15_16584 crossref_primary_10_4161_cc_10_15_16585 crossref_primary_10_1080_2162402X_2021_1950953 crossref_primary_10_3389_fphar_2023_1237456 crossref_primary_10_1007_s10585_014_9645_6 crossref_primary_10_1038_cddis_2016_202 crossref_primary_10_3390_cancers17010155 crossref_primary_10_3390_ijms22062981 crossref_primary_10_1016_j_ceb_2017_05_006 crossref_primary_10_1111_odi_13652 crossref_primary_10_1007_s13402_021_00604_1 crossref_primary_10_1016_j_drup_2021_100752 crossref_primary_10_1038_srep10867 crossref_primary_10_1016_j_cmet_2019_01_015 crossref_primary_10_3389_fcell_2023_1274682 crossref_primary_10_1186_s12967_025_06831_6 crossref_primary_10_1080_15384101_2016_1252882 crossref_primary_10_1016_j_biomaterials_2018_01_023 crossref_primary_10_1053_j_seminoncol_2017_10_004 crossref_primary_10_1186_s40170_016_0149_5 crossref_primary_10_1089_ars_2011_4243 crossref_primary_10_1016_j_freeradbiomed_2022_10_271 crossref_primary_10_1089_ars_2011_4367 crossref_primary_10_3390_ijms221910874 crossref_primary_10_1007_s13277_013_1167_3 crossref_primary_10_4161_cc_25510 crossref_primary_10_1002_jcp_30419 crossref_primary_10_3390_ani12010020 crossref_primary_10_1016_j_bcp_2023_115464 crossref_primary_10_1111_hel_12944 crossref_primary_10_3389_fceld_2024_1337724 crossref_primary_10_3390_cancers12092349 crossref_primary_10_1002_ctm2_2 crossref_primary_10_1002_mc_23233 crossref_primary_10_1016_j_bbadis_2021_166262 crossref_primary_10_1016_j_drup_2025_101273 crossref_primary_10_1016_j_trsl_2017_07_004 crossref_primary_10_1155_2014_603980 crossref_primary_10_1007_s00408_014_9639_9 crossref_primary_10_1016_j_biopha_2023_114762 crossref_primary_10_1002_rmb2_12577 crossref_primary_10_1016_j_cbi_2021_109602 crossref_primary_10_3389_fonc_2020_572904 crossref_primary_10_1038_s41388_018_0423_9 crossref_primary_10_1016_j_ajpath_2012_03_017 crossref_primary_10_1016_j_critrevonc_2025_104820 crossref_primary_10_1038_s41419_018_0795_3 crossref_primary_10_1080_15548627_2018_1450020 crossref_primary_10_1016_j_yexmp_2018_11_014 crossref_primary_10_1186_2049_3002_2_2 crossref_primary_10_1038_nrclinonc_2016_60 crossref_primary_10_1186_s12964_023_01129_w crossref_primary_10_1186_1475_2867_12_6 crossref_primary_10_1016_j_bbadis_2024_167164 crossref_primary_10_1002_iub_2569 crossref_primary_10_1080_15548627_2016_1203483 crossref_primary_10_1186_1471_2407_14_1 crossref_primary_10_4161_cc_22820 crossref_primary_10_1101_gad_345629_120 crossref_primary_10_4161_cc_10_24_18487 crossref_primary_10_1186_bcr2892 crossref_primary_10_1007_s00428_019_02735_1 crossref_primary_10_1002_1873_3468_70139 crossref_primary_10_3892_ol_2014_2385 crossref_primary_10_1016_j_matbio_2024_06_004 crossref_primary_10_4161_cc_10_11_15674 crossref_primary_10_1080_15384101_2018_1520566 crossref_primary_10_4161_cc_10_11_15675 crossref_primary_10_1007_s13277_013_0707_1 crossref_primary_10_3390_ph13070156 crossref_primary_10_1016_j_canlet_2014_07_028 crossref_primary_10_1016_j_semcancer_2014_01_005 crossref_primary_10_4161_cc_22316 crossref_primary_10_1155_2017_7454031 crossref_primary_10_1186_1476_4598_12_93 crossref_primary_10_3390_ijms232415576 crossref_primary_10_3389_fonc_2017_00081 crossref_primary_10_1053_j_seminoncol_2014_03_002 crossref_primary_10_3389_fonc_2018_00625 crossref_primary_10_3389_fonc_2021_603224 crossref_primary_10_1186_s43556_024_00233_8 crossref_primary_10_3390_cells12232742 crossref_primary_10_1080_01652176_2024_2419585 crossref_primary_10_1172_JCI191943 crossref_primary_10_1038_s41388_019_0805_7 crossref_primary_10_1002_adbi_202200233 crossref_primary_10_1016_j_ijpharm_2020_119882 crossref_primary_10_3389_fimmu_2017_00939 crossref_primary_10_1038_onc_2013_121 crossref_primary_10_1186_s13578_015_0005_2 crossref_primary_10_3390_metabo15030203 crossref_primary_10_4161_auto_28773 crossref_primary_10_1080_10715762_2018_1489133 crossref_primary_10_3390_cancers13133146 crossref_primary_10_1186_s13046_021_02046_x crossref_primary_10_1186_s40364_020_00257_6 crossref_primary_10_1007_s13277_014_2482_z crossref_primary_10_1016_j_mad_2015_04_003 crossref_primary_10_1016_j_fct_2021_112159 crossref_primary_10_4161_cc_19841 crossref_primary_10_1002_ijc_27664 crossref_primary_10_3389_fonc_2021_700629 crossref_primary_10_1002_ijc_31369 crossref_primary_10_3389_fonc_2022_924290 crossref_primary_10_1016_j_imbio_2015_06_018 crossref_primary_10_1016_j_prp_2023_154723 crossref_primary_10_3390_ijms131113764 crossref_primary_10_18632_oncotarget_26078 crossref_primary_10_1186_s12943_025_02297_8 crossref_primary_10_1016_j_bbcan_2014_06_002 crossref_primary_10_3390_cancers14010020 crossref_primary_10_3892_or_2021_8159 crossref_primary_10_1186_1471_2407_13_500 crossref_primary_10_3390_cancers6031570 crossref_primary_10_1155_2022_5277440 crossref_primary_10_1016_j_semcdb_2015_02_013 crossref_primary_10_4161_cc_20718 crossref_primary_10_1007_s12032_024_02525_z crossref_primary_10_4161_cc_20717 crossref_primary_10_3389_fcell_2021_622908 crossref_primary_10_3892_or_2013_2828 crossref_primary_10_1080_14789450_2018_1500902 crossref_primary_10_4161_cc_22226 crossref_primary_10_1073_pnas_1112129109 crossref_primary_10_1172_JCI143763 crossref_primary_10_1080_09553002_2022_2063432 crossref_primary_10_1080_15592294_2016_1140295 crossref_primary_10_4161_cc_10_15_16870 crossref_primary_10_1002_adhm_201300294 crossref_primary_10_1016_j_semcancer_2015_02_007 crossref_primary_10_1242_dmm_021071 crossref_primary_10_3390_vaccines8020172 crossref_primary_10_3892_mmr_2017_7804 crossref_primary_10_3389_fcell_2020_00796 crossref_primary_10_3389_fbioe_2025_1547757 crossref_primary_10_3892_ol_2014_2225 |
| Cites_doi | 10.1073/pnas.92.5.1381 10.4161/auto.6.6.12574 10.1016/j.cell.2007.12.018 10.1074/jbc.M112274200 10.1073/pnas.0602235103 10.1016/j.cmet.2006.01.012 10.4161/cc.9.11.11848 10.1074/jbc.M001914200 10.1128/MCB.00166-09 10.1038/sj.cdd.4401838 10.4161/cbt.7.8.6220 10.4161/cc.8.23.10238 10.4161/cbt.8.11.8874 10.4161/auto.8822 10.2353/ajpath.2009.080658 10.1038/45257 10.4161/cbt.10.2.11983 10.1016/j.cmet.2006.02.002 10.1002/pros.20946 10.1016/j.cell.2006.05.036 10.2353/ajpath.2007.060661 10.1016/j.humpath.2008.06.018 10.1158/0008-5472.CAN-05-1235 10.1074/jbc.M205948200 10.4161/cc.9.16.12553 10.2353/ajpath.2009.080653 10.1002/emmm.201000073 10.1016/S0046-8177(96)90214-2 10.1128/MCB.25.17.7546-7556.2005 10.1002/hep.22753 10.1152/jn.1972.35.4.405 10.1073/pnas.95.20.11715 10.1016/j.cbi.2005.12.009 10.4161/cc.8.11.8544 10.2353/ajpath.2009.080873 10.1074/jbc.272.36.22642 10.4161/cc.9.12.12048 10.1074/jbc.M008340200 10.1038/nature06905 10.1158/1541-7786.MCR-07-0309 10.1074/jbc.M110970200 10.1016/j.ccr.2009.12.041 10.1016/j.cmet.2005.05.001 10.1093/emboj/17.22.6633 10.1113/jphysiol.2003.058131 10.1038/nrc1877 10.1158/0008-5472.CAN-07-5127 10.4161/cc.9.17.12721 10.2353/ajpath.2009.080924 10.1097/01.ju.0000138082.68045.48 10.4161/auto.8788 10.1074/jbc.M800102200 10.1038/emboj.2009.242 10.1016/j.bbrc.2005.08.111 10.1042/bj20021279 10.1038/emboj.2009.364 10.1111/j.1582-4934.2008.00615.x 10.1016/S0891-5849(00)00364-6 10.1038/nrc2618 10.1128/MCB.01396-08 10.1016/j.molcel.2004.08.025 10.1158/0008-5472.CAN-09-2211 10.1158/1078-0432.CCR-08-0732 10.1038/sj.onc.1209937 10.1074/jbc.272.26.16374 10.1038/sj.onc.1201661 |
| ContentType | Journal Article |
| Copyright | Copyright © 2010 Landes Bioscience 2010 |
| Copyright_xml | – notice: Copyright © 2010 Landes Bioscience 2010 |
| DBID | 0YH AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.4161/cc.9.17.12928 |
| DatabaseName | Taylor & Francis Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 0YH name: Taylor & Francis Open Access url: https://www.tandfonline.com sourceTypes: Publisher – sequence: 3 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| EISSN | 1551-4005 |
| EndPage | 3533 |
| ExternalDocumentID | PMC3047617 20855962 10_4161_cc_9_17_12928 10912928 |
| Genre | Research Article Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NIAMS NIH HHS grantid: R01 AR055660 – fundername: NCI NIH HHS grantid: R01 CA120876 – fundername: NCI NIH HHS grantid: R01 CA080250 – fundername: NCI NIH HHS grantid: R01 CA075503 – fundername: NCI NIH HHS grantid: P30 CA056036 – fundername: NCI NIH HHS grantid: R01-CA-75503 – fundername: NCI NIH HHS grantid: R01-CA-86072 – fundername: NCI NIH HHS grantid: P30-CA-56036 – fundername: NCI NIH HHS grantid: R01-CA-120876 – fundername: NCI NIH HHS grantid: R01-CA-080250 |
| GroupedDBID | --- 0BK 0R~ 0YH 29B 30N 4.4 53G 5GY AAGDL AAHBH AAHIA AAJMT AALDU AAMIU AAPUL AAQRR ABCCY ABFIM ABFMO ABJNI ABLIJ ABPAQ ABPEM ABTAI ABXUL ABXYU ACFTK ACGFS ACTIO ADBBV ADCVX ADGTB AEISY AENEX AEXWM AEYOC AFRVT AGDLA AHDZW AIJEM AIYEW AKBVH AKOOK ALMA_UNASSIGNED_HOLDINGS ALQZU AOIJS AQRUH AQTUD AVBZW AWYRJ BAWUL BLEHA CCCUG DGEBU DIK DKSSO E3Z EBS EJD F5P GTTXZ H13 HYE KRBQP KWAYT KYCEM M4Z O9- OK1 P2P RNANH ROSJB RPM RTWRZ SJN SNACF TASJS TBQAZ TDBHL TEI TFL TFT TFW TQWBC TR2 TTHFI TUROJ ZGOLN - 0R AAAVI ABJVF ABQHQ ADACO AEGYZ AFOLD AHDLD AIRXU FUNRP FVPDL UNR V1K ZA5 AAGME AAYXX ACDHJ ACZPZ ADOPC AURDB BFWEY C1A CITATION CWRZV EMOBN IPNFZ LJTGL PCLFJ RIG ADYSH CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c482t-3e64b80953b6b2a0945d9718fb786a5dde965d88df75594701f9785a376538033 |
| IEDL.DBID | TFW |
| ISICitedReferencesCount | 351 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000281621700025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1538-4101 1551-4005 |
| IngestDate | Tue Nov 04 01:57:39 EST 2025 Thu Oct 02 10:30:34 EDT 2025 Wed Feb 19 02:31:20 EST 2025 Sat Nov 29 03:33:06 EST 2025 Tue Nov 18 22:06:57 EST 2025 Fri Jan 15 03:37:36 EST 2021 Tue May 21 11:32:56 EDT 2019 Mon Oct 20 23:42:55 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 17 |
| Language | English |
| License | open-access: http://creativecommons.org/licenses/by-nc/3.0/: This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c482t-3e64b80953b6b2a0945d9718fb786a5dde965d88df75594701f9785a376538033 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://www.tandfonline.com/doi/abs/10.4161/cc.9.17.12928 |
| PMID | 20855962 |
| PQID | 756660303 |
| PQPubID | 23479 |
| PageCount | 19 |
| ParticipantIDs | pubmed_primary_20855962 proquest_miscellaneous_756660303 crossref_primary_10_4161_cc_9_17_12928 crossref_citationtrail_10_4161_cc_9_17_12928 informaworld_taylorfrancis_310_4161_cc_9_17_12928 pubmedcentral_primary_oai_pubmedcentral_nih_gov_3047617 landesbioscience_primary_cc_article_12928 |
| PublicationCentury | 2000 |
| PublicationDate | 9/1/2010 2010/09/01 2010-09-00 2010-Sep-01 20100901 |
| PublicationDateYYYYMMDD | 2010-09-01 |
| PublicationDate_xml | – month: 09 year: 2010 text: 9/1/2010 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Cell cycle (Georgetown, Tex.) |
| PublicationTitleAlternate | Cell Cycle |
| PublicationYear | 2010 |
| Publisher | Taylor & Francis Landes Bioscience |
| Publisher_xml | – name: Taylor & Francis – name: Landes Bioscience |
| References | R63 R62 R21 R20 R64 R23 R22 R25 R24 R68 R27 R26 R29 R28 Zhao H (R60) 2009; 69 R1 R2 R3 R4 Sato T (R65) 1968; 17 R6 R7 R30 Stathopoulos GT (R49) 2008; 6 R32 R31 R34 R33 R36 Gherghiceanu M (R53) 2009; 13 R35 R38 R37 R39 Jung Y (R15) 2003; 370 Singh H (R61) 2004; 172 Kong D (R41) 2005; 65 Mills E (R8) 1972; 35 Moles A (R59) 2009; 49 Razani B (R45) 2002; 277 R40 R43 R42 R44 R47 R46 Perkins ND (R13) 2006; 25 R48 Mueller L (R51) 2007; 171 Hanai J (R67) 2002; 277 Schofield CJ (R5) 2005; 338 R50 An J (R18) 2005; 25 R52 R10 R54 R12 R56 R11 R55 R14 R58 R57 R16 Schubert W (R66) 2002; 277 R17 Wyatt CN (R9) 2004; 556 R19 |
| References_xml | – ident: R28 doi: 10.1073/pnas.92.5.1381 – ident: R54 doi: 10.4161/auto.6.6.12574 – ident: R26 doi: 10.1016/j.cell.2007.12.018 – volume: 277 start-page: 16464 year: 2002 ident: R67 publication-title: J Biol Chem doi: 10.1074/jbc.M112274200 – ident: R14 doi: 10.1073/pnas.0602235103 – ident: R1 doi: 10.1016/j.cmet.2006.01.012 – ident: R44 doi: 10.4161/cc.9.11.11848 – ident: R11 doi: 10.1074/jbc.M001914200 – ident: R24 doi: 10.1128/MCB.00166-09 – ident: R12 doi: 10.1038/sj.cdd.4401838 – ident: R32 doi: 10.4161/cbt.7.8.6220 – ident: R63 doi: 10.4161/cc.8.23.10238 – ident: R36 doi: 10.4161/cbt.8.11.8874 – ident: R22 doi: 10.4161/auto.8822 – ident: R64 doi: 10.2353/ajpath.2009.080658 – ident: R25 doi: 10.1038/45257 – ident: R35 doi: 10.4161/cbt.10.2.11983 – ident: R2 doi: 10.1016/j.cmet.2006.02.002 – volume: 69 start-page: 991 year: 2009 ident: R60 publication-title: Prostate doi: 10.1002/pros.20946 – ident: R43 doi: 10.1016/j.cell.2006.05.036 – volume: 171 start-page: 1608 year: 2007 ident: R51 publication-title: Am J Pathol doi: 10.2353/ajpath.2007.060661 – ident: R55 doi: 10.1016/j.humpath.2008.06.018 – volume: 65 start-page: 9047 year: 2005 ident: R41 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-05-1235 – volume: 277 start-page: 40091 year: 2002 ident: R66 publication-title: J Biol Chem doi: 10.1074/jbc.M205948200 – ident: R39 doi: 10.4161/cc.9.16.12553 – ident: R68 doi: 10.2353/ajpath.2009.080653 – ident: R48 doi: 10.1002/emmm.201000073 – volume: 17 start-page: 158 year: 1968 ident: R65 publication-title: J Electron Microsc (Tokyo) – ident: R57 doi: 10.1016/S0046-8177(96)90214-2 – volume: 25 start-page: 7546 year: 2005 ident: R18 publication-title: Mol Cell Biol doi: 10.1128/MCB.25.17.7546-7556.2005 – volume: 49 start-page: 1297 year: 2009 ident: R59 publication-title: Hepatology doi: 10.1002/hep.22753 – volume: 35 start-page: 405 year: 1972 ident: R8 publication-title: J Neurophysiol doi: 10.1152/jn.1972.35.4.405 – ident: R10 doi: 10.1073/pnas.95.20.11715 – ident: R6 doi: 10.1016/j.cbi.2005.12.009 – ident: R37 doi: 10.4161/cc.8.11.8544 – ident: R33 doi: 10.2353/ajpath.2009.080873 – ident: R3 doi: 10.1074/jbc.272.36.22642 – ident: R40 doi: 10.4161/cc.9.12.12048 – ident: R62 doi: 10.1074/jbc.M008340200 – ident: R16 doi: 10.1038/nature06905 – volume: 6 start-page: 364 year: 2008 ident: R49 publication-title: Mol Cancer Res doi: 10.1158/1541-7786.MCR-07-0309 – volume: 277 start-page: 8635 year: 2002 ident: R45 publication-title: J Biol Chem doi: 10.1074/jbc.M110970200 – ident: R52 doi: 10.1016/j.ccr.2009.12.041 – ident: R4 doi: 10.1016/j.cmet.2005.05.001 – ident: R31 doi: 10.1093/emboj/17.22.6633 – volume: 556 start-page: 175 year: 2004 ident: R9 publication-title: J Physiol doi: 10.1113/jphysiol.2003.058131 – ident: R38 doi: 10.4161/cc.8.23.10238 – ident: R27 doi: 10.1038/nrc1877 – ident: R58 doi: 10.1158/0008-5472.CAN-07-5127 – ident: R46 doi: 10.4161/cc.9.17.12721 – ident: R34 doi: 10.2353/ajpath.2009.080924 – volume: 172 start-page: 2421 year: 2004 ident: R61 publication-title: J Urol doi: 10.1097/01.ju.0000138082.68045.48 – ident: R23 doi: 10.4161/auto.8788 – ident: R19 doi: 10.1074/jbc.M800102200 – ident: R42 doi: 10.1038/emboj.2009.242 – volume: 338 start-page: 617 year: 2005 ident: R5 publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2005.08.111 – volume: 370 start-page: 1011 year: 2003 ident: R15 publication-title: Biochem J doi: 10.1042/bj20021279 – ident: R20 doi: 10.1038/emboj.2009.364 – volume: 13 start-page: 202 year: 2009 ident: R53 publication-title: J Cell Mol Med doi: 10.1111/j.1582-4934.2008.00615.x – ident: R47 doi: 10.1016/S0891-5849(00)00364-6 – ident: R50 doi: 10.1038/nrc2618 – ident: R21 doi: 10.1128/MCB.01396-08 – ident: R7 doi: 10.1016/j.molcel.2004.08.025 – ident: R17 doi: 10.1158/0008-5472.CAN-09-2211 – ident: R56 doi: 10.1158/1078-0432.CCR-08-0732 – volume: 25 start-page: 6717 year: 2006 ident: R13 publication-title: Oncogene doi: 10.1038/sj.onc.1209937 – ident: R29 doi: 10.1074/jbc.272.26.16374 – ident: R30 doi: 10.1038/sj.onc.1201661 |
| SSID | ssj0028791 |
| Score | 2.4922633 |
| Snippet | Recently, using a co-culture system, we demonstrated that MCF7 epithelial cancer cells induce oxidative stress in adjacent cancer-associated fibroblasts,... |
| SourceID | pubmedcentral proquest pubmed crossref landesbioscience informaworld |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 3515 |
| SubjectTerms | Animals Antirheumatic Agents - pharmacology Apoptosis Regulatory Proteins Autophagy Binding Biology Bioscience Breast Neoplasms - metabolism Breast Neoplasms - pathology Calcium Cancer Caveolin 1 - genetics Caveolin 1 - metabolism Cell Cell Hypoxia Cell Line, Tumor Cell Survival Chloroquine - pharmacology Coculture Techniques Cycle Female Fibroblasts - metabolism Glutathione Synthase - antagonists & inhibitors Glutathione Synthase - metabolism Humans Hypoxia-Inducible Factor 1, alpha Subunit - metabolism Intracellular Signaling Peptides and Proteins - metabolism Landes Membrane Proteins - metabolism Mice Mice, Knockout Microtubule-Associated Proteins - metabolism NF-kappa B - metabolism Organogenesis Oxidative Stress Paracrine Communication Proteins Proto-Oncogene Proteins - metabolism RNA Interference RNA, Small Interfering - metabolism Stromal Cells - metabolism Tumor Microenvironment Tumor Suppressor Proteins - metabolism Up-Regulation |
| Subtitle | Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment |
| Title | Autophagy in cancer associated fibroblasts promotes tumor cell survival |
| URI | https://www.tandfonline.com/doi/abs/10.4161/cc.9.17.12928 http://www.landesbioscience.com/journals/cc/article/12928/ https://www.ncbi.nlm.nih.gov/pubmed/20855962 https://www.proquest.com/docview/756660303 https://pubmed.ncbi.nlm.nih.gov/PMC3047617 |
| Volume | 9 |
| WOSCitedRecordID | wos000281621700025&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAWR databaseName: Taylor & Francis Online Journals customDbUrl: eissn: 1551-4005 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0028791 issn: 1538-4101 databaseCode: TFW dateStart: 20020101 isFulltext: true titleUrlDefault: https://www.tandfonline.com providerName: Taylor & Francis |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagAgkOlFdhW6h8QEhIZMnDGzvHasXSAyocilhOlp90JUhWeSD13zPjZKPdwl7gkktsJ_GM52FPvo-QV9ayIvEsi3jGWMS8ZpEo8jRSiqc61QoMYgBx_cgvLsRyWXzeovrCskrMoX0PFBFsNS5upQMDCYbj74yZFtOET8FVpfibL7h85C64XHwdUy3BiwEpVUQMtK5H1_yz94432sEqvU8OsbQQT2kGVEn3tyD0Zi3llnNaHP7HZz0kD4aIlJ71KvSI3HLlY3K356i8fkI-nHWIPaC-X9NVSQ0qSU3VIFRnqYd8u9IQg7cNXYfaPtfQtvtZ1RQPBWjTgTECdX5KvizeX87Po4F9ITJMpG2UuZxpgXB0OtepgjRwZgvwZF5zkasZmMUin1khrOeQlTAeJx4y0pkCiwWzHmfZETkoq9I9J1SlXsRGQKgSW5b7uLCe2dg4zhTX3vkJebuRgjQDNDkyZPyQkKLg3EhjZCETLsPcTMjrsfm6x-TY1zDZFqlswyaI7xlLZLanT3RT7uNDPnUtbjlUdTmfhx5rC-_-Zm97GHhY_5ux6UaBJKxilIIqXdU1kkNUnYO9zSbkWa9P4yBIoooUSRPCdzRtbIAA4bt3ytVVAArHI1WIUI__YRpOyL2-TgI3m16Qg7bu3Etyx_xqV019Sm7H387hypfiNCy8341_Mhc |
| linkProvider | Taylor & Francis |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lj9MwELZgAS0cWB4LlKcPCAlpXfJwYue4qliKKIXDIi0ny_EDKkFS5YG0_56ZJI22C73AtRk7zbzHHn1DyEtreRZ6HjMRc864zzmTWRoxrUWUR7kGh9iBuC7EcinPzrLPQ1dlPbRVYg3te6CIzlejceNhNFo45uNvjJlm01BMIVZF8iq5luDEbNDl4Ot8LLbgpwErVTIOetfja_65fCsebaGV3iIH2FyI9zQDrqT7Wxp6uZvyQng6OfifD7tDbg9JKT3uteguueKKe-RGP6by_D55d9wi_ID-dk5XBTWoJxXVg1ydpR5K7jKHNLyp6bpr73M1bdqfZUXxXoDWLfgj0OhD8uXk7elszoYBDMxwGTUsdinPJSLS5WkeaagEE5tBMPO5kKlOwDNmaWKltF5AYcJFEHooShMNTgvYHsTxA7JXlIV7RKiOvAyMhGwlsDz1QWY9t4FxgmuRe-cn5GgjBmUGdHIckvFDQZWCvFHGqEyFQnW8mZBXI_m6h-XYRRhelKlqunMQ3w8tUfGONeyy4MeXfGobPHUoq2I261asLfz31zvpYePBBWz2phsNUmDIKAVduLKtlYDEOgWXG0_Iw16hxk1wjipOSZoQsaVqIwFihG8_KVbfO6xwvFWFJPXxP7DhBdmfn35cqMX75Ycn5GbfNoHNdU_JXlO17hm5bn41q7p63lneb-DRNDQ |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BgQoOlEeB8PQBISE1Sx7e2DlWCwuIaumhiN4sx7FhJUhWeSD13zOTZKPdwl7gnLGjeF7fxKNvAF7mOU9Dx2NfxJz73GXcl2kS-VqLKIsyjQGxI3E9EYuFPD9PTzdGfVFbJdXQrieK6GI1Ofcqd-TgBMffGDNJJ6GYYKqK5FW4hpA5obrrbP51rLWkSAeqVOlzNLueXvPP5VvpaIus9BYcUG8hXdMMtJL2byj0cjPlRnaaH_zHd92B2wMkZce9Dd2FK7a4Bzf6IZUX9-H9cUvkA_rbBVsWzJCVVEwPWrU5c1hwlxmC8KZmq665z9asaX-WFaNbAVa3GI3Qng_hy_zd2eyDP4xf8A2XUePHNuGZJD66LMkijXXgNE8xlblMyERPMS6myTSXMncCyxIugtBhSTrVGLLw1IM4fgB7RVnYR8B05GRgJGKVIOeJC9Lc8TwwVnAtMmedB0drLSgzcJPTiIwfCmsUOhtljEpVKFR3Nh68GsVXPSnHLsFwU6Wq6f6CuH5kiYp3rPEv6318yee2oX8OZVXMZt0KVJ8Hr3fK48ZDAFjvzdYGpNCNSQu6sGVbK4GwOsGAG3vwsLencROaokozkjwQW5Y2ChBD-PaTYvm9YwqnO1WEqI__4RhewP7p27k6-bj49ARu9j0T1Fn3FPaaqrXP4Lr51Szr6nnnd78BlHQzIQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Autophagy+in+cancer+associated+fibroblasts+promotes+tumor+cell+survival%3A+Role+of+hypoxia%2C+HIF1+induction+and+NF%CE%BAB+activation+in+the+tumor+stromal+microenvironment&rft.jtitle=Cell+cycle+%28Georgetown%2C+Tex.%29&rft.au=Martinez-Outschoorn%2C+Ubaldo+E&rft.au=Trimmer%2C+Casey&rft.au=Lin%2C+Zhao&rft.au=Whitaker-Menezes%2C+Diana&rft.date=2010-09-01&rft.eissn=1551-4005&rft.volume=9&rft.issue=17&rft.spage=3515&rft_id=info:doi/10.4161%2Fcc.9.17.12928&rft_id=info%3Apmid%2F20855962&rft.externalDocID=20855962 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1538-4101&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1538-4101&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1538-4101&client=summon |